Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$23.5 - $35.38 $242,708 - $365,404
-10,328 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$29.21 - $44.64 $301,680 - $461,041
10,328 New
10,328 $335,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Alpha Crest Capital Management LLC Portfolio

Follow Alpha Crest Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.